Termination of Bridge Biotherapeutics’s Collaboration and License Agre..
On November 9, 2020, Bridge Biotherapeutics reported to the Korea Stock Exchange that the Company and Boehringer Ingelhe..
Bridge Biotherapeutics Announces Detailed Plans for the Phase 2a Study..
- The data from the low dose cohort confirms the safety and efficacy of BBT-401, Bridge Biotherapeutics’ novel drug cand..
Bridge Biotherapeutics Announces 2:1 Bonus Issue
Bridge Biotherapeutics announced that the company’s board of directors approved the issuance of new shares through a 2:1..
Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea and BaseLaunc..
Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR..
Following the US FDA's IND clearance,South Korea's MFDS cleared the IND application of BBT-176, submitted inDecember 201..
Bridge Biotherapeutics Discloses Interim Results from the First Cohort..
The Interim data showed that 3 out of 9 evaluable patients on BBT-401 responded with more than 30% reduction in Total Ma..
Bridge Biotherapeutics Acquires a New Drug Development Candidate for B..
Signed a collaboration and license agreement for developing back-eye disease treatments with Konkuk University in the Re..
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGF..
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced th..